CPRX News & Events

H.C. Wainwright downgraded Catalyst Pharmaceuticals to Neutral from Buy with a $31.50 price target after the company agreed to be acquired by Angelini Pharma at a price of $31.50 per share in cash. The firm does not expect an additional bidder to emerge.

Reports Q1 revenue $149.4M, consensus $148.18M. FIRDAPSE Q1 2026 product revenue, net was $98.9 million, an 18.1% year-over-year increase, primarily driven by increases in sales volumes. AGAMREE Q1 2026 product revenue, net was $36.7 million, compared to product revenue, net of $22.0 million in Q1 2025. The results underscore continued sales volume growth and increasing prescriber engagement. FYCOMPA Q1 2026 product revenue, net was $13.8 million, a 61.3% year-over-year decrease following loss of exclusivity in 2025.

In light of the Company's May 7, 2026 announcement, Catalyst will not be providing forward-looking guidance or updates to previously issued guidance. In addition, the Company will not host an earnings conference call or webcast reporting on its first quarter 2026 results.

Citi downgraded Catalyst Pharmaceuticals to Neutral from Buy with a $31.50 price target after Angelini Pharma announced it will acquire Catalyst for $4.1B, or $31.50 per share. The firm believes the acquisition price "falls within the range of fairly valuing Catalyst's business," sees low risk of another bidder coming to the table and anticipates the deal will close without issue.